Axovia Therapeutics: Funding, Investors & Team (Oct 2026)
Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.
Axovia Therapeutics has raised $2.1M across 2 funding rounds on record, the most recent an undisclosed round of $1.1M announced in Jan 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Axovia Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Axovia Therapeutics Funding Rounds
Axovia Therapeutics raised $1.0M in an undisclosed round announced in Oct 2024.
1.3 years later, an undisclosed round of $1.1M was announced in Jan 2026.
Axovia Therapeutics Founders and Leadership Team
Contact details for the Axovia Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Axovia Therapeutics Funding Compared to Other Biotechnology Startups
Axovia Therapeutics' latest round of $1.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Axovia Therapeutics in Biotechnology and London
Companies Similar to Axovia Therapeutics
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Axovia Therapeutics Funding FAQs
What does Axovia Therapeutics do?
Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.
How much funding has Axovia Therapeutics raised?
Axovia Therapeutics has raised $2.1M across 2 rounds on record. The most recent is an undisclosed round of $1.1M announced in Jan 2026.
When did Axovia Therapeutics last raise funding?
Axovia Therapeutics' most recent funding round on record is an undisclosed round of $1.1M, announced in Jan 2026.
Who founded Axovia Therapeutics?
FundedIQ lists Philip Beales (Founder), Victor Hernandez (Founder) at Axovia Therapeutics.
Where is Axovia Therapeutics headquartered?
Axovia Therapeutics is based in London, England, United Kingdom.
How many employees does Axovia Therapeutics have?
Axovia Therapeutics is in the 11-50 employee band.
How does Axovia Therapeutics' funding compare to other Biotechnology startups?
Axovia Therapeutics' latest round of $1.1M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Axovia Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Axovia Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.